SCHEMBL27161719

SCHEMBL27161719

O=C1OCCN1c1ccc(S(=O)(=O)N2CCC3(CCN(Cc4cc(F)ccc4F)CC3)CC2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ CYP2D6 P10635 3/20 0.40
▸ SSTR5 P35346 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ GRM5 P41594 3/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ HTR2A P28223 2/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ PKM P14618 3/20 0.36
▸ USP2 O75604 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ ADORA2B P29275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30049321 1.00 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2LMNACYP2D6SSTR5
SCHEMBL30050112 0.95 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2LMNACYP2D6SSTR5
SCHEMBL27162170 0.95 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2LMNACYP2D6SSTR5
SCHEMBL30050705 0.91 CYP3A4 (0.40) ALDH1A1SMN1; SMN2LMNACYP2D6L3MBTL1
SCHEMBL30050026 0.91 CYP3A4 (0.44) ALDH1A1SMN1; SMN2LMNACYP2D6L3MBTL1
SCHEMBL27161544 0.91 CYP3A4 (0.44) ALDH1A1SMN1; SMN2LMNACYP2D6L3MBTL1
SCHEMBL27162324 0.91 CYP3A4 (0.40) ALDH1A1SMN1; SMN2LMNACYP2D6L3MBTL1
SCHEMBL30050034 0.90 SMN1; SMN2 (0.43) ALDH1A1SMN1; SMN2LMNACYP2D6SSTR5
SCHEMBL27162198 0.90 SMN1; SMN2 (0.43) ALDH1A1SMN1; SMN2LMNACYP2D6SSTR5
SCHEMBL30049542 0.85 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2LMNACYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US claimed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 ALDH1A1 1011/4885SMN1; SMN2 3118/4885LMNA 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback